Premier Research Re-brands its Medical Device Business Unit to D-TARGET
Premier Research Group announces the re-branding of its Medical Device business unit to D-TARGET, a Premier Research Company. With the continued growth in clinical development activity driven by rising regulatory and commercial demands in the medical device industry, Premier Research recognizes this sector has specific needs.
D-TARGET was founded in 1997 and acquired by Premier Research in 2007. By reintroducing the name, Premier Research reinforces its focus on this sector and highlights the capability, expertise, and experience gained by its staff operating as a dedicated Medical Device Contract Research Organization.
This division offers a team of medical device specialists with experience in the European Union and North America. D-TARGET’s staff is located in more than 30 countries with primary offices in Yverdon, Switzerland and Boston, Massachusetts. Sponsors directly benefit from regional employees with their knowledge of the local clinical research environment and ability to communicate with investigators and regulatory bodies in their own local language.
D-TARGET continues to offer a total life cycle partnership for developers of medical device and combination products, ranging from: strategic and tactical advisory services, clinical trial set-up, and clinical trial operations through to post marketing surveillance and registry support. In conjunction with the clinical operational staff, D-TARGET has specialist support groups dedicated to: regulatory affairs, ethical committee, competent authority, and country specific submissions, protocol writing, statistical analysis, and data management, thereby enabling our teams to meet the full range of needs of medical device developers worldwide.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
